Oncology as a field focuses on the medical aspect of studying, diagnosis, and treatment of tumors. For most people this seems to be one of the difficult careers in the world, however to one oncologist Mikhail Blagosklonny, nothing could be further from the truth. Mikhail Blagosklonny is a man passionate about his area of specialty, and he is on a mission of making more people aware of it too. Thanks to his friend, Dr. Andrei Gudkov and the two, ran the successful peer-reviewed publication Oncotarget thus ensuring that medical research findings are made available to everybody in the world.
Read more: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget
Education and Career
Dr. Mikhail has a well-decorated CV. Mikhail education journey starts and ends at First Pavlov State Medical University in St. Petersburg. It is here that Mikhail completed his M.D. studies in internal medicine and Ph.D. in cardiology and experimental medicine.
Career wise, Dr. Mikhail started off in 2002 as an associate professor of medicine at New York Medical College, Valhalla. With his scholarly nature, Mikhail progressed to become a senior scientist at the Ordway Research Institute in New York. While at Ordway he excelled in his position giving him the position to maintain his position and at the same time helping him build on his skills for his next assignment. When the opportunity presented itself in 2009, Dr. Mikhail’s took it and joined the Roswell Park Cancer Institute where he works to date as an oncology professor.
Blagosklonny’s Role at Roswell Park Cancer Institute
To say the least, Dr. Mikhail Blagosklonny is a seasoned researcher with a deep interest in cancer and aging. While in Roswell Park Cancer Institute Dr. Mikhail efforts have been greatly felt and appreciated more so in the Department of Cell Stress Biology of the Institutions. In addition to the original concepts to be used in cancer treatment developed by Mikhail, he has gone forth to co-found and edit an oncology-based publication known as Oncotarget.
Through Oncotarget, Dr. Mikhail has also contributed in the academia by publishing more than two hundred medical articles that have been cited and published by many researchers. This has helped create a lot of awareness about scientific research. Download output styles at Endnote.com
Dr. Weisfogel is one of the best well known dentists in New Jersey, New York. He has a great passion for dentistry. He is the owner of Dental Sleep Masters, founded in 2014 where he focus on the treatments of sleep apnea and other patient’s problems. He has focused on helping patients with sleep apnea and other sleep disorders using oral appliances. He works with other dentists to identify the cause and treatments for their different problems.
In fact most of his individual patients are referrals from other dentists who have not found the right treatment for their patients. Dr. Weisfogel is a an undergraduate from Rutgers University with a BA in biology and psychology. He also holds a DDS from New York University college of Dentistry and more information click here.
Before establishing his Dental Sleep Masters, he worked at Old Bridge Dental care as a dentist where he focused on individualized patient care. From 2007 to 2013 he was recognized by the Consumer Research Council for being the best cosmetic, implant and sedation dentist. The dental sleep master was a passion that he has had for over 15 years where he had a dream to develop solutions to the treatment of sleep apnea medical condition.
Since Dr. Weisfogel began his career in 2002, he has developed more than 100 therapies to assist in the treatment of sleep apnea patients. There is no known cure for sleep apnea hence the use of therapies. He has also been working with other dentists to develop more knowledge and other solutions to the sleeping disorder conditions.
Dr. Weisfogel has also been supporting an international charity Operational Smile GOFundMe campaign that aims at bringing back the smiles of children and young adults through free surgical procedures. The campaign operates on children and young adults who suffer from cleft palate, cleft lips and other face deformities.
Each year the Operational Smile camps in different countries with medical missions ready to help the communities. He targets $2, 000 that will be donated to operation smile. He believes that children should always get the best and have hope of tomorrow. They are our future and need the best care and contact him.
Oncotarget is a journal that is posted weekly by peer reviews involving Oncology topics. It is a free place for physicians, students and researchers to go to read about others findings and concerns about medical topics.
The journal was created in 2010 by Mikhail Blagosklonny and Andrei V. Gudkov, who hold the positions of editor-in-chief. The journal is published by Impact Journals.
Oncotarget focuses on such topics as,
• Cell Death
The journal is a place where anyone in the medical field can go to learn from others that have had similar experiences when dealing with cancer issues on YouTube. It is like a free study group where anyone can go and get free access to a number of articles.
Some main targets looked at within the journal are things such as,
• Pathological research
• Targets involving cancer and the way the cells attack a body
• Treatments that have benefited patients with the disease
• Therapy that is used and others in the medical field can learn from.
Having a weekly journal like Oncotarget is a huge benefit to the medical field. A medical student can have all the free articles they want to study about the field.
Researchers can post their own findings and maybe even find some new clues to oncology from their peers. Medical staff that specializes in the Oncology field can find treatments and therapy that has been used by others and possibly share it with their own patients.
Oncotarget is a medical journal on bioxbio.com that goes over all aspects of oncology and has proven over the test of time that many have found its content useful and helpful in the treatment of their patients and research.
Learn more about Oncotarget: